局部晚期前列腺癌终身内分泌治疗联合或不联合根治性放疗后的第二癌症:SPCG-7试验长期随访
SPCG-7随机试验长期随访显示,局部晚期前列腺癌患者在内分泌治疗基础上联合70 Gy前列腺放疗后,第二癌症总体风险未显著增加(HR 1.19,95%CI 0.92-1.54),但膀胱癌风险增加(HR 2.54,95%CI 1.14-5.69),且多数为浅表性;放疗带来的总生存获益(HR 0.73,95%CI 0.62-0.86)超过膀胱癌风险。
要点
- 联合放疗组膀胱癌风险增加(HR 2.54),但85%为浅表性。
- 联合放疗组总生存获益明确,死亡风险降低(HR 0.73)。
- salvge放疗患者第二癌症风险降低(HR 0.48),需进一步验证。
核心结论
- 联合放疗虽增加膀胱癌风险,但总生存获益超过该风险。
- 第二癌症尤其是膀胱癌风险应与患者讨论并纳入随访计划。
研究设计与样本
- SPCG-7随机对照试验(1996-2002年)纳入875例局部晚期非转移性前列腺癌患者。
- 本分析纳入651例挪威和209例瑞典患者,随访数据来自两国癌症和死因登记。
- 患者随机接受单纯内分泌治疗或内分泌治疗联合70 Gy前列腺放疗。
主要发现
- 中位随访12.2年(第二癌症分析)和12.6年(总生存分析),联合放疗组与单纯内分泌组分别431例和429例。
- 联合放疗组第二癌症125例 vs 168例,总第二癌症HR 1.19(95%CI 0.92-1.54)。
- 膀胱癌HR 2.54(95%CI 1.14-5.69),总数31例(联合组23例,单纯组8例),85%为浅表性。
- salvge放疗患者第二癌症HR 0.48(95%CI 0.24-0.94)。
- 中位总生存:单纯内分泌组12.8年(95%CI 11.8-13.8),联合放疗组15.3年(95%CI 14.3-16.4);联合放疗组死亡HR 0.73(95%CI 0.62-0.86), salvge放疗患者死亡HR 0.44(95%CI 0.30-0.65)。
临床怎么用
- 对接受前列腺放疗的局部晚期前列腺癌患者,应告知膀胱癌风险增加并制定相应随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Curative radiation therapy (RT) constitutes a cornerstone in prostate cancer (PC) treatment. We present long-term follow-up estimates for second cancer (SC) risk and overall survival (OS) in patients randomized to hormone therapy (ET) alone or combined with 70 Gy prostatic RT in the Scandinavian Prostate Cancer Group-7 (SPCG-7) study. We explored the effect of salvage RT (≥60 Gy to the ET group) and reported causes of death. METHODS AND MATERIALS: The SPCG-7 study (1996-2002) was a randomized controlled trial that included 875 men with locally advanced nonmetastatic PC. In this analysis, including data from the Norwegian and Swedish Cancer and Cause of Death registries for 651 Norwegian and 209 Swedish study patients, we estimated hazard ratios (HRs) for SC and death, and cumulative incidences of SC. RESULTS: Median follow-up of the 860 (431 ET and 429) ET + RT patients was 12.2 years for SC risk analysis and 12.6 years for the OS analysis. Eighty-three of the Norwegian ET patients received salvage RT, and median time to salvage RT was 5.9 years. We found 125 and 168 SCs in the ET and ET + RT patients, respectively. With ET alone as reference, ET + RT patients had an HR of 1.19 (95% confidence interval [CI], 0.92-1.54) for all SCs and 2.54 (95% CI, 1.14-5.69) for urinary bladder cancer (UBC). The total number of UBC was 31 (23 in ET + RT; 8 in ET), and the vast majority (85%) were superficial. The HR for SC in salvage RT patients was 0.48 (95% CI, 0.24-0.94). Median OS was 12.8 (95% CI, 11.8-13.8) and 15.3 (95%, CI 14.3-16.4) years in the ET and ET + RT groups, respectively. Compared with ET alone, the risk of death was reduced in ET + RT patients (HR, 0.73; 95% CI, 0.62-0.86) and in ET patients receiving salvage RT (HR, 0.44; 95% CI, 0.30-0.65). CONCLUSIONS: Although the risk of UBC was increased in PC patients who received RT in addition to ET, this disadvantage is outweighed by the OS benefit of RT confirmed in our study. The risk of SC, and especially UBC, should be discussed with patients and be reflected in follow-up programs.
引用
- Aksnessæther BY, Myklebust TÅ, Solberg A, et al. Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 31786279. doi:10.1016/j.ijrobp.2019.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。